Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  buparlisib
Find trials that include:  Any drugs shown
Results 1-16 of 16 for your search:
Start Over
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CBKM120F2303, NCI-2013-00017, 2012-002571-34, NCT01633060
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCRI CNS 13, NCI-2015-00813, NCT01349660
Buparlisib and Cetuximab in Treating Patients with Recurrent or Metastatic Head and Neck Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-1972, NCI-2013-00586, BKM120, NCT01816984
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2204, NCI-2014-00156, NCT01870726
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2108, NCI-2014-01570, NCT02088684
PI3K Inhibitor BKM120 in Treating Patients With Refractory Advanced Solid Tumors That Have PIK3CA Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-211, NCI-2012-00257, NCT01501604
PI3K inhibitor BKM120 in Treating Patients With High-Risk, Localized Prostate Cancer Undergoing Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 85
Trial IDs: 115516, NCI-2013-01830, CBKM120ZUS26T, UCSF CC# 115516, NCT01695473
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719A2201, NCI-2014-00149, NCT01923168
Buparlisib in Treating Patients with Relapsed or Refractory Thymomas
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IUCRO-0478, NCI-2014-01946, NCT02220855
Buparlisib or Alpelisib and Capecitabine, Trastuzumab, or Lapatinib Ditosylate in Treating Patients with Metastatic Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1024, NCI-2013-00951, 11-0060, NCT01300962
PI3K Inhibitor BKM120 and Everolimus in Treating Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WCI1925-10, NCI-2012-00210, IRB00048549, NCT01470209
Buparlisib or Alpelisib and Olaparib in Treating Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-159, NCI-2012-01929, CBKM120ZUS32T, ISS22810064, NCT01623349
PI3K Inhibitor BKM120 and Rituximab in Treating Patients with Relapsed or Refractory B-Cell Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-13027, NCI-2014-00110, 2013C0156, NCT02049541
Buparlisib, Cisplatin, and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-008, NCI-2014-02351, NCT02113878
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Winship2494-13, NCI-2015-00652, CBKM120ZUS36T, OSUCC-OFA-BKM120-CLL, NCT02614508
Erismodegib and Buparlisib in Treating Patients with Advanced or Metastatic Basal Cell Carcinoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SKIN0020, NCI-2014-02200, 5136, NCT02303041
Start Over